Tumor-initiating capacity of CD138-and CD138+ tumor cells in the 5T33 multiple myeloma model

Leukemia

Volumn 26, Issue 6, 2012, Pages 1436-1439

  Van Valckenborgh, E ^a   Matsui, W ^b   Agarwal, P ^c   Lub, S ^a   Dehui, X ^a   De Bruyne, E ^a   Menu, E ^a   Empsen, C ^a   Van Grunsven, L ^a   Agarwal, J ^b   Wang, Q ^b   Jernberg Wiklund, H ^c   Vanderkerken, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 3; CASPASE 7; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PANOBINOSTAT; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; STAT3 PROTEIN; SYNDECAN 1; TANESPIMYCIN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

B LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DISEASE MODEL; EMBRYONIC STEM CELL; ENZYME ACTIVITY; HUMAN; LETTER; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; SYNDECAN-1; TUMOR CELLS, CULTURED;

EID: 84859905863     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.373     Document Type: Letter

References (13)

1. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. (Pubitemid 33041634)
3. Rasmussen T, Lodahl M, Hancke S, Johnsen HE. In multiple myeloma clonotypic CD38-/CD19 +CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004; 45: 1413-1417. (Pubitemid 38701919)
4. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 2008; 26: 2895-2900.
5. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003; 194: 196-206. (Pubitemid 36896125)
6. Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102: 311-319. (Pubitemid 36759670)
7. Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, Hose D et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 2010; 316: 1816-1828.
8. Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010; 5: e11483.
9. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010; 116: 5465-5475.
10. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576-3582. (Pubitemid 29536154)
11. Dongkyoon K, Weissman I. Enrichment of xenotransplantable clonal cells in CD38high/CD138+ cells of multiple myeloma patients. AACR 101st Annual Meeting, Abstract 4315 2010.
12. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337. (Pubitemid 47106366)
13. Reid S, Yang S, Brown R, Kabani K, Aklilu E, Ho PJ et al. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 2010; 32 (6 Part 1): e190-e196.